BDTX-1535-101, NCT05256290: Phase 1/2 Study of BDTX-1535 in Patients with Glioblastoma or Non-Small Cell Lung Cancer with EGFR Mutations |
|
|
| Recruiting | 1/2 | 200 | US | BDTX-1535 monotherapy | Black Diamond Therapeutics, Inc. | Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation | 07/25 | 06/26 | | |
| Terminated | 1 | 29 | Europe, US, RoW | PBI-200 | Pyramid Biosciences, Pyramid Biosciences, Inc., Pyramid Biosciences | Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor | 07/23 | 07/23 | | |
